HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects

[1] Thompson MA(2010)Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 321-333

[2] Aberg JA(2002)Abacavir hypersensitivity reaction Clin Infect Dis 34 1137-1142

[3] Cahn P(2008)HLA-B*5701 screening for hypersensitivity to abacavir N Engl J Med 358 568-579

[4] Hewitt RG(2008)High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients Clin Infect Dis 46 1111-1118

[5] Mallal S(2002)Risk factor analysis of hypersensitivity reactions to abacavir Clin Ther 24 565-573

[6] Phillips E(2007)Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards AIDS Res Hum Retrovir 23 1374-1376

[7] Carosi G(2016)Adverse events associated with abacavir use in HIV-infected children and adolescents: a systemic review and meta-analysis Lancet HIV 3 e64-e75

[8] Saag M(2002)Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 727-732

[9] Balu R(2010)Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients HIV Clin Trials 11 69-79

[10] Phillips E(2008)African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping Ann Rev Genom Hum Genet 9 403-433

[1] Thompson MA(2010)Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 321-333

[2] Aberg JA(2002)Abacavir hypersensitivity reaction Clin Infect Dis 34 1137-1142

[3] Cahn P(2008)HLA-B*5701 screening for hypersensitivity to abacavir N Engl J Med 358 568-579

[4] Hewitt RG(2008)High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients Clin Infect Dis 46 1111-1118

[5] Mallal S(2002)Risk factor analysis of hypersensitivity reactions to abacavir Clin Ther 24 565-573

[6] Phillips E(2007)Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards AIDS Res Hum Retrovir 23 1374-1376

[7] Carosi G(2016)Adverse events associated with abacavir use in HIV-infected children and adolescents: a systemic review and meta-analysis Lancet HIV 3 e64-e75

[8] Saag M(2002)Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 727-732

[9] Balu R(2010)Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients HIV Clin Trials 11 69-79

[10] Phillips E(2008)African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping Ann Rev Genom Hum Genet 9 403-433